In millions, except per share items | Sep-30-18 | Jun-30-18 | Mar-31-18 | Dec-31-17 | Sep-30-17 | Jun-30-17 | Mar-31-17 | Dec-31-16 |
| 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
Cash flows used in operating activities: | | | | | | | | |
Net loss | -85.9 | -58.2 | -66.3 | -77.1 | -130.8 | -220.7 | -199.1 | -169.6 |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
Depreciation | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.9 | 0.8 | 0.7 |
Amortization of intangibles | 13.5 | 29.3 | 46.1 | | 54.8 | 101.5 | 83.4 | |
Amortization of deferred financing costs | 3.8 | 3.7 | 3.6 | 3.3 | 3.0 | 3.9 | 3.1 | 2.4 |
Accretion expense | 9.0 | 8.8 | 8.8 | 8.6 | 8.2 | 10.7 | 8.5 | 6.5 |
PIK Interest | 1.4 | 1.0 | 0.5 | | | | | |
Stock compensation expense | 1.9 | 2.0 | 2.1 | 2.5 | 2.6 | 4.1 | 3.5 | 2.7 |
Unrealized foreign currency loss | 0.7 | | | | | | | |
Fair market value change in contingent consideration | | -0.4 | -1.1 | -1.0 | -2.4 | -12.2 | -11.3 | -11.7 |
Fair market value change in derivative liability | -0.1 | -0.2 | -0.4 | 0.0 | -2.2 | -8.9 | -8.6 | -8.9 |
Gain from legal settlement | | | | | -10.5 | | | |
Gain from exchange of debt | -0.1 | | | | -14.7 | | | |
Impairment of fixed assets | 18.6 | | | 18.5 | 53.8 | | | 56.1 |
Gain on sale of assets | | -0.4 | | | | | | |
(Increase) decrease in operating assets, net of effects of acquisitions: | | | | | | | | |
Accounts receivable | 9.5 | 10.0 | -6.0 | 5.4 | -3.6 | 16.5 | 30.7 | 11.0 |
Income tax receivable | 0.4 | 0.4 | 0.6 | 1.3 | 2.9 | 6.3 | 6.1 | 5.3 |
Inventory | 6.3 | 3.4 | 2.0 | 2.4 | 0.2 | 1.6 | 2.6 | 2.3 |
Prepaid expenses and other assets | -6.4 | -7.7 | -7.3 | -9.4 | -7.8 | 2.2 | 0.6 | 0.2 |
Increase (decrease) in operating liabilities, net of effects of acquisitions: | | | | | | | | |
Accounts payable and accrued expenses | 0.6 | -4.7 | -2.3 | -2.1 | -3.9 | -7.1 | -9.7 | -8.0 |
Accrued allowances | 0.5 | -1.7 | 4.4 | -4.7 | 1.9 | -6.9 | -6.9 | -1.7 |
Interest payable | 0.5 | -0.4 | -0.8 | -0.5 | -0.7 | -1.6 | -5.6 | -1.0 |
Other liabilities | -2.7 | -2.2 | -2.0 | -2.2 | -2.2 | -4.3 | -4.5 | -2.6 |
Net cash used in operating activities | -22.1 | -4.8 | -5.4 | -5.9 | -2.8 | -4.9 | 3.5 | 1.0 |
Cash flows from investing activities: | | | | | | | | |
Acquisition of Orexigen, net of cash acquired | -69.2 | | | | | | | -0.6 |
Proceeds from sale of non-core assets | | 0.4 | | | | | | |
Purchase of software and equipment | -0.2 | -0.1 | 0.0 | 0.0 | 0.0 | | -1.9 | -1.7 |
Net cash used in investing activities | -66.9 | 2.3 | 2.0 | 2.0 | 0.0 | | 0.0 | -0.3 |
|
Cash flows from financing activities: | | | | | | | | |
Proceeds from issuance of convertible notes | | | | | | | | |
Tax benefit on stock-based awards | | | | | | | | |
Proceeds from exercise of stock options | | | | | | | | |
Proceeds from 2018 Term Loan | 41.3 | | | | | | | |
Net proceeds from Delayed Draw Term Loan | 9.2 | | | | 30.0 | | | |
Payments on Treximet Secured Notes | | | -10.1 | | -17.5 | | -33.2 | |
Payment on financing costs | | | -13.8 | -13.6 | -13.6 | | | |
Net payments on credit facilities | | | | | 0.2 | | | |
Payments on mortgages and capital leases | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 |
Proceeds from issuance of common stock, net of tax and costs | | 1.6 | | | 1.1 | | | |
Shares withheld for the payment of taxes | -0.1 | -0.1 | | -0.1 | -0.1 | | | 0.0 |
Stock issuance costs | -0.5 | | | | | | | |
Net cash provided by financing activities | 86.2 | 8.1 | 7.6 | 0.4 | 1.6 | -9.9 | -9.9 | -13.0 |
Effect of exchange rate changes on cash and cash equivalents | 0.1 | | | | | | | |
Net decrease in cash and cash equivalents | -2.7 | 5.6 | 4.2 | -3.6 | -1.3 | -14.9 | -6.5 | -12.3 |
Cash and cash equivalents, beginning of period | | | 32.8 | | | | 73.0 | |
Cash and cash equivalents, end of period | 30.1 | 38.4 | 37.0 | 32.8 | 35.1 | 21.5 | 59.1 | 73.0 |